Sponsor Pipeline

Suzhou Genhouse Bio Co., Ltd. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
7
Active Trials
3
Recruiting
2
Disease Areas
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-02 NCT06310382
GH55 for Advanced Cancers With MAPK Mutations: A Study on Safety and Early Results
overall status: Recruiting → Unknown
Active Trials by Phase
Phase 2
1
Phase 1/2
3
Phase 1
3
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT07318649 Phase 2 Clinical Study to Evaluate the Efficacy, Safety, Tolerability, and… Locally Advanced or Metastatic Solid Tumors Not Yet Recruiting
Phase 1/2
NCT06306456 A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets… Non-Small Cell Lung Cancer With EGFR Mutation Recruiting
NCT06435455 GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation Not Yet Recruiting
NCT07446725 A Study to Evaluate Safety, PK and Efficacy of GH55 in Combination With GH21 in Patients… Advanced Solid Tumor Cancer Not Yet Recruiting
Phase 1
NCT06329206 A Phase Ia/Ib Study of GH2616 Tablet in Subjects With Advanced Solid Tumors Advanced Solid Tumors Recruiting
NCT06796699 A Phase Ia/Ib Clinical Study of GH56 Capsules in Subjects With MTAP-Deleted Advanced… Advanced Solid Tumors With MTAP Gene Deletion Recruiting
NCT07260513 A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary… Advanced Solid Tumor Cancer Active, Not Recruiting
Disease Areas
Get alerts when Suzhou Genhouse Bio Co., Ltd.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free